Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
FDA Approves Wegovy HD: Highest-Dose GLP-1 Delivers 21% Weight Loss
FDA approved 7.2mg semaglutide injection in record 54 days, delivering 20.7% average weight loss - the most effective obesity treatment ever approved.
The DoseFDA Proposes to Block Mass GLP-1 Compounding in Historic Access Shift
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk list, effectively ending large-scale compounding that provided $150-300 monthly alternatives.
The DoseBreakthrough Study: Semaglutide Shows Promise for Alcohol Addiction Treatment
Major Lancet study reveals weekly semaglutide significantly reduces alcohol craving and consumption in people with alcohol use disorder and obesity, opening new treatment pathways.
The DoseFDA Fast-Tracks Foundayo Approval: GLP-1 Pill With No Timing Restrictions
Eli Lilly's Foundayo becomes first GLP-1 pill that can be taken anytime without food restrictions, launching at $149/month through record-fast FDA approval.
The DoseFDA Opens Comment Period to Permanently End GLP-1 Bulk Compounding
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list permanently, seeking public comments through June 29, 2026 before final decision.
The DoseOral GLP-1 Drugs Target Brain's Reward Center for First Time, NIH Study Finds
Small-molecule GLP-1 drugs penetrate deep into the brain to suppress pleasure-based eating and potentially addiction by targeting the central amygdala.
The DoseFDA Moves to Permanently End Large-Scale GLP-1 Compounding in Historic Shift
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk compounding list, effectively ending affordable compounded alternatives that cost $200-400 monthly versus $1000+ for brand drugs.
The DoseFDA Moves to Ban Large-Scale GLP-1 Compounding in Major Access Shift
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk drug list, effectively ending large-scale compounding of affordable GLP-1 alternatives that cost $200-400 monthly vs $1000+ for brand drugs.
The DoseFDA Fast-Tracks Foundayo Approval: Second GLP-1 Pill Offers More Freedom
Eli Lilly's Foundayo becomes second FDA-approved GLP-1 pill with no food or timing restrictions, launching at $149/month through record-fast approval process.
The DoseNovo's Wegovy Pill Surge Forces Wall Street to Rethink Eli Lilly's Dominance
Novo Nordisk's Wegovy pill launch has doubled telehealth provider business overnight and reached tens of thousands of new patients, challenging expectations about Eli Lilly's GLP-1 market leadership.
The DoseMedicare Launches $50 GLP-1 Coverage Starting July as Historic Access Barrier Falls
CMS will provide Medicare beneficiaries access to Wegovy, Zepbound, and Foundayo for $50/month starting July 1, 2026, marking the first time Medicare covers weight loss medications.
The DoseMajor Study Shows GLP-1 Drugs Cut Heart and Kidney Disease Risk in Type 1 Diabetes
Johns Hopkins analysis of 175,000 Type 1 diabetes patients shows GLP-1 drugs reduce heart disease risk by 15% and kidney failure by 19% without safety concerns.